885271-93-2 Usage
Description
5-fluoro-1H-Indazole-3-acetic acid, ethyl ester is a chemical compound with the molecular formula C11H10FN2O2. It is an ethyl ester derivative of 5-fluoro-1H-Indazole-3-acetic acid, which is a fluorinated indazole derivative. 5-fluoro-1H-Indazole-3-acetic acid,ethyl ester is a potential drug candidate and has been studied for its potential therapeutic applications, including its anti-inflammatory and analgesic properties. Its ethyl ester form makes it more soluble in organic solvents and suitable for use in pharmaceutical formulations. It is a promising compound for further research and development in the field of medicinal chemistry.
Uses
Used in Pharmaceutical Industry:
5-fluoro-1H-Indazole-3-acetic acid, ethyl ester is used as a potential drug candidate for its anti-inflammatory and analgesic properties. Its ethyl ester form enhances its solubility in organic solvents, making it suitable for pharmaceutical formulations and improving its therapeutic efficacy.
Used in Medicinal Chemistry Research:
5-fluoro-1H-Indazole-3-acetic acid, ethyl ester is used as a promising compound for further research and development in the field of medicinal chemistry. Its unique structure and properties make it a valuable subject for exploring new therapeutic applications and optimizing its pharmaceutical potential.
Check Digit Verification of cas no
The CAS Registry Mumber 885271-93-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,8,5,2,7 and 1 respectively; the second part has 2 digits, 9 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 885271-93:
(8*8)+(7*8)+(6*5)+(5*2)+(4*7)+(3*1)+(2*9)+(1*3)=212
212 % 10 = 2
So 885271-93-2 is a valid CAS Registry Number.
885271-93-2Relevant articles and documents
NITROGEN-CONTAINING FUSED RING COMPOUNDS FOR USE AS CRTH2 ANTAGONISTS
-
Paragraph 0112, (2014/11/13)
The present application relates to nitrogen-containing fused ring compounds shown by general formula (I), a pharmaceutically acceptable salt thereof and a stereoisomer thereof as CRTH2 antagonist, wherein X1, X2, X3, X4, X5, W, X, Y, L1, L2, L3, A, B are as defined in the description; the present application further relates to a method for preparing the compounds, a pharmaceutical formulation and a pharmaceutical composition comprising the compounds, a use of the compounds for the manufacture of a medicament for the treatment and/or prevention of diseases related to activity of CRTH2.
